A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment.
about
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexateThe relationships between the cardiovascular effects, alpha- and beta-adrenoceptor blocking actions and plasma concentration of labetalol in doca hypertensive ratsTAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple ParadigmsOverlapping but distinct effects of genistein and ethinyl estradiol (EE(2)) in female Sprague-Dawley rats in multigenerational reproductive and chronic toxicity studiesImmunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extractPreserved leftward movement in left unilateral spatial neglect due to frontal lesions.Determination of the di-(2-ethylhexyl) phthalate NOAEL for reproductive development in the rat: importance of the retention of extra animals to adulthood.Fourteen-week toxicity study of green tea extract in rats and mice.Effects of the PPARĪ± Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism.Exposure to hexavalent chromium resulted in significantly higher tissue chromium burden compared with trivalent chromium following similar oral doses to male F344/N rats and female B6C3F1 mice.Reproductive toxicity of di-n-butylphthalate in a continuous breeding protocol in Sprague-Dawley rats.Multiple comparisons in long-term toxicity studies.Toxicity and carcinogenicity of androstenedione in F344/N rats and B6C3F1 mice.Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium.Contribution of soil esterase to biodegradation of aliphatic polyester agricultural mulch film in cultivated soils.Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava.Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: implications for carcinogenic modes of action.Nonparametric bayes testing of changes in a response distribution with an ordinal predictorImpact of Environmental Enrichment Devices on NTP In Vivo Studies.Biomarkers of Dose and Effect of Inhaled Ozone in Resting versus Exercising Human Subjects: Comparison with Resting Rats.Pulmonary lesions in female Harlan Sprague-Dawley rats following two-year oral treatment with dioxin-like compoundsA comparative 90-day toxicity study of allyl acetate, allyl alcohol and acrolein.Hexavalent chromium is carcinogenic to F344/N rats and B6C3F1 mice after chronic oral exposure.Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment.Aloin, a Component of the Aloe Vera Plant Leaf, Induces Pathological Changes and Modulates the Composition of Microbiota in the Large Intestine of F344/N Male Rats.Comparative pulmonary toxicity of inhaled metalworking fluids in rats and mice.Evaluation of Nonacog Beta Pegol Long-term Safety in the Immune-deficient Rowett Nude Rat (Crl:NIH-Foxn1rnu).Relation between colour vision loss and occupational styrene exposure level.Statistical issues on the no-observed-adverse-effect level in categorical response.Methotrexate and erythro-9-(2-hydroxynon-3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism.Thyroid follicular lesions induced by oral treatment for 2 years with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds in female Harlan Sprague-Dawley rats.A 13-week nose-only inhalation toxicity study for perfluoro-n-butyl iodide (PFBI) in rats with recommended occupational exposure levels.The toxicological properties of petroleum gases.Nonparametric step-down test procedures for finding minimum effective dose.Cardiac damage in rodents after exposure to bis(2-chloroethoxy)methane.TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Comparative toxicity and tissue distribution of antimony potassium tartrate in rats and mice dosed by drinking water or intraperitoneal injection.Toxicity, DNA binding, and cell proliferation in male F344 rats following short-term gavage exposures to trans-2-hexenal.Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.
P2860
Q24658507-821B5899-68F8-4946-8D2F-B11690B06D66Q28317572-E1F6C7E8-454F-488C-8B07-972E2F1214CEQ28384192-0D23C6AE-F92D-402D-BECB-A1F0EFD9A971Q28389598-F9AAA60D-2A16-408B-89A6-995BDD6A3435Q28577347-26748CD3-82C5-46EC-B420-F66DB32E235FQ33733100-78543B0A-9E74-4021-9D6B-260288407728Q34000807-2A82C030-F364-4376-BABF-80CE3B149700Q34024170-A291EF20-7C95-4128-AF6B-008E2DD9C26CQ34189111-A4C76B62-2CAE-40C1-B4A3-F726C8A33677Q34322078-823F98F2-5F19-48A5-8576-A51C898BAC82Q34637912-96B22BC1-0C3A-426F-B7D6-55DF61791154Q35031188-18FDCE6F-63CE-4DF4-8321-D5A41E3A0FC3Q35141504-BE4BBFE0-10D3-4EF8-9AEF-5F52E76174A7Q35188516-0CECAD05-ACF1-417D-A5A7-95A0721B6456Q35264348-73B1EBD0-180E-40AA-B373-510CC7B4C2EEQ35300791-7891B497-2910-46EB-96D9-F921042119B8Q35626804-41344BB8-C93C-4D9D-A8E4-DC9A5B02DB95Q36667365-8EE3F4D4-D386-404F-93E2-7187ACFBBAADQ36669650-945ACB50-B844-419A-B5F3-0B1C411C2610Q36873546-842632D0-F379-45B3-9F17-838B8F75787EQ37077861-7CA3B740-634E-48F8-A133-005D5D08EBA5Q37150646-8BED1C81-33E1-4F10-A0E5-1DBEDF102442Q37201176-6669912F-A74D-4092-B9B7-CCB34D009FD9Q37561128-574C5D5B-C187-4FB5-8BF0-A2F3B3EC48B5Q38774379-DA25D934-17D6-4BBF-AB95-A7DD4B736D0EQ39656116-3EDF04F8-9FDC-4B49-8180-923F1C29E0D6Q40768285-18088161-89C0-42CE-9FB7-A758BCCB4DB0Q41872732-B9181E61-A565-4A6A-AB10-DB1B6CF8ED4CQ41981282-2ED66F7A-4E37-4007-96F8-D31370C9353EQ42109128-C399A7AA-8FCC-473D-844B-6543024C8088Q42869188-0EAAFBD7-394E-4A51-B3C0-0B5A7224540EQ43052768-2E2E10FF-E59D-4BF0-9D54-61E132F13293Q43582040-7720118F-3351-4055-9EFE-5B5397ED4E77Q44871472-B2343A10-81A7-448A-BB7A-1DDEA1525E31Q44942444-339CBA06-F0E0-498B-B5B2-77AFBFF133E4Q45298693-0803F827-48AA-426B-A95F-E8634F0B2FF0Q45778975-7603D1AE-92B3-4203-A69D-EAEBFB67B600Q46474854-4673DEA5-7738-485A-8B1C-45686B3813D6Q46686084-10F272D1-F7B0-4934-A266-13061BC6840BQ46781523-0486A3D8-05AC-4473-8C2D-10F3A07AE515
P2860
A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment.
description
1977 nĆ® lÅ«n-bĆ»n
@nan
1977幓ć®č«ę
@ja
1977幓å¦ęÆęē«
@wuu
1977幓å¦ęÆęē«
@zh-cn
1977幓å¦ęÆęē«
@zh-hans
1977幓å¦ęÆęē«
@zh-my
1977幓å¦ęÆęē«
@zh-sg
1977幓åøč”ęē«
@yue
1977幓åøč”ęē«
@zh
1977幓åøč”ęē«
@zh-hant
name
A non-parametric equivalent of ...... ng dose levels of a treatment.
@en
A non-parametric equivalent of ...... ng dose levels of a treatment.
@nl
type
label
A non-parametric equivalent of ...... ng dose levels of a treatment.
@en
A non-parametric equivalent of ...... ng dose levels of a treatment.
@nl
prefLabel
A non-parametric equivalent of ...... ng dose levels of a treatment.
@en
A non-parametric equivalent of ...... ng dose levels of a treatment.
@nl
P356
P1433
P1476
A non-parametric equivalent of ...... ng dose levels of a treatment.
@en
P2093
P304
P356
10.2307/2529789
P407
P577
1977-06-01T00:00:00Z